Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Table 2 Association between VEGF genotypes and overall survival

Genotypes	Case No.	Deaths No. (%)*	MST (95% CI, month)	Crude HR (95% CI)	P ^†	Adjusted HR (95% CI)	P ^‡
*VEGF*-460T > C (rs833061)
TT	33	28 (84.9)	16.0 (11.0-25.0)	1.00		1.00
CT	67	47 (70.2)	21.0 (17.0-32.0)	0.60 (0.37-0.95)	0.031	0.56 (0.34-0.90)	0.018
CC	24	17 (70.8)	27.0 (10.0-36.0)	0.75 (0.41-1.37)	0.347	0.67 (0.36-1.26)	0.212
CT+CC	91	64 (70.3)	21.0 (17.0-31.0)	0.63 (0.40-0.99)	0.043	0.58 (0.37-0.92)	0.022
*VEGF* -634G > C (rs2010963)
GG	57	40 (70.2)	23.0 (16.0-36.0)	1.00		1.00
CG	41	34 (82.9)	17.0 (13.0-25.0)	1.20 (0.76-1.90)	0.440	1.17 (0.74-1.88)	0.502
CC	26	18 (69.2)	12.0 (9.0-29.0)	1.25 (0.71-2.18)	0.436	1.28 (0.72-2.28)	0.399
CG+CC	67	52 (76.1)	17.0 (12.0-24.0)	1.22 (0.80-1.84)	0.356	1.21 (0.79-1.84)	0.379
*VEGF* +936C > T (rs3025039)
CC	92	68 (73.9)	21.0 (16.0-29.0)	1.00		1.00
CT	30	22 (73.3)	17.0 (11.0-29.0)	1.08 (0.67-1.75)	0.742	1.00 (0.60-1.66)	0.992
TT	2	2 (100)	14.5 (9.0-20.0)	2.14 (0.52-8.80)	0.291	1.95 (0.46-8.29)	0.367
CT+TT	32	24 (75.0)	17.0 (11.0-28.0)	1.13 (0.71-1.80)	0.606	1.05 (0.65-1.71)	0.839

Abbreviation: MST, median survival time.
* Percentage of deaths in each stratum
† P values were calculated using the log-rank test in the univariate analysis.
‡ P values were obtained from the Cox hazards model with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of chemotherapy and radiotherapy dose.

ISSN: 1471-2407